Erythropoiesis stimulating agents (ESAs) for congestive heart failure: the red and the black.

Abstract	CHF is a disease of high incidence and prevalence in the elderly. Anemia is associated with an increased mortality in these patients. Erythropoietin secretion is reduced in these patients due to complexed mechanisms. Although some improvement in quality of life has been shown when using ESAs it has not been found any decrement on mortality. Moreover, safety reports suggest an increased risk of thromboembolic event. Together with the high drug cost, the use of ESAs cannot be recommended for the treatment of CHF patients.
Authors	Nicolás Roberto Robles, Juan Francisco Macias, Julio Herrera
Journal	European journal of internal medicine (Eur J Intern Med) Vol. 25 Issue 2 Pg. 193-6 (Feb 2014) ISSN: 1879-0828 [Electronic] Netherlands
PMID	24491240 (Publication Type: Journal Article)
Copyright	Copyright © 2013 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
Chemical References	Hematinics
Topics	Aged Anemia (complications, drug therapy) Anemia, Iron-Deficiency (complications, drug therapy) Cardio-Renal Syndrome (complications) Drug Costs Heart Failure (complications) Hematinics (economics, therapeutic use) Humans Kidney Failure, Chronic (complications)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!